MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Galena Biopharma Company Profile (NASDAQ:GALE)

Consensus Ratings for Galena Biopharma (NASDAQ:GALE) (?)
Ratings Breakdown: 1 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $3.94 (83.14% upside)

Analysts' Ratings History for Galena Biopharma (NASDAQ:GALE)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016FBR & Co.Reiterated RatingOutperform$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Noble FinancialReiterated RatingPositive$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016OppenheimerReiterated RatingOutperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015Cantor FitzgeraldUpgradeSell -> Hold$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Raymond JamesInitiated CoverageOutperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015MLV & Co.Reiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2015Needham & Company LLCSet Price TargetBuy$7.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Galena Biopharma (NASDAQ:GALE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/10/2016Q1($0.06)($0.07)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.05)($0.07)$2.61 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.07)($0.11)$4.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.09)($0.10)$3.54 million$3.38 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.09)($0.08)$3.47 million$2.75 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414($0.11)($0.06)$2.58 million$3.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.11)($0.05)$2.66 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.09)($0.17)$2.99 million$2.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.10)($0.02)$2.09 million$2.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.09)($0.46)$1.62 million$1.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q213($0.10)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2013Q4 2012($0.62)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.09)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Galena Biopharma (NASDAQ:GALE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.05)($0.05)($0.05)
Q2 20161($0.08)($0.08)($0.08)
Q3 20161($0.08)($0.08)($0.08)
Q4 20162($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)
Dividend History for Galena Biopharma (NASDAQ:GALE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Galena Biopharma (NASDAQ:GALE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/12/2014Richard ChinDirectorSell187,500$4.33$811,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014Rudolph NisiDirectorBuy20,000$4.94$98,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Mark SchwartzCOOSell100,000$5.57$557,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Sanford HillsbergDirectorSell250,000$5.41$1,352,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2014Rudolph NisiDirectorSell250,000$5.28$1,320,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2014Steven KriegsmanDirectorSell450,000$6.52$2,934,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Rudolph NisiDirectorSell200,000$6.90$1,380,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Galena Biopharma (NASDAQ:GALE)
DateHeadline
06/23/16 08:10 AMGalena Biopharma (GALE) is Overbought: Is A Drop Coming? -
06/23/16 07:04 AMGalena Biopharma (NASDAQ:GALE) Analyst Rating Consensus - Trade Calls
06/22/16 08:47 AMGalena Biopharma, Inc. (GALE) Current Analyst Ratings - Fiscal Standard
06/21/16 03:53 PMHC Stocks Alerts: Galena Biopharma Inc (NASDAQ:GALE), Gilead Sciences, Inc. (NASDAQ:GILD) - share market updates (press release)
06/21/16 03:53 PMStocks within Analysts Screening: Galena Biopharma, Inc. (NASDAQ:GALE) , Mylan N.V. (NASDAQ:MYL) - Street Updates
06/20/16 03:58 PMBiotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen - PR Newswire (press release)
06/20/16 03:58 PMStocks within Analysts Screening: Abbott Laboratories (NYSE:ABT) , Galena Biopharma, Inc. (NASDAQ:GALE) - Street Updates
06/20/16 03:58 PMGalena Biopharma: Rejecting The Return Of The Cancer - Seeking Alpha
06/20/16 10:22 AMBiotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
06/17/16 03:59 PMGalena Biopharma, Inc. Upside Stock Momentum at Extreme Strength - CML News
06/16/16 04:10 PMEarnings Stocks Analysis: Galena Biopharma, Inc. (NASDAQ:GALE), SM Energy Company (NYSE:SM) - Beacon Chronicle
06/15/16 04:13 PMAnalysts Lay Out The Case For Two Biotechs: Galena Biopharma Inc (GALE) and Marinus Pharmaceuticals Inc (MRNS) - Smarter Analyst
06/15/16 04:13 PMAnalysts Lay Out The Case For Two Biotechs: Galena Biopharma Inc (GALE) and Marinus Pharmaceuticals Inc (MRNS) - Smarter Analyst
06/14/16 08:56 AMPrice Target Spotlight: Galena Biopharma, Inc. (NASDAQ:GALE) - News Oracle
06/13/16 03:52 PMGalena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
06/10/16 10:16 PMStock Update (NASDAQ:GALE): Galena Biopharma Inc Receives Two Orphan Drug Designations for GALE-301 and ... - Smarter Analyst
06/10/16 10:16 PMGalena Biopharma Inc. (GALE) Jumps 5.05% on June 10 - Equities.com
06/10/16 01:47 PMGalena Biopharma Receives Two Orphan Drug Designations for GALE-301 and GALE-301/GALE-302 - [GlobeNewswire] - SAN RAMON, Calif., June 10, 2016-- Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical ...
06/09/16 04:15 PMHC Stocks Broker Alerts: Galena Biopharma Inc (NASDAQ:GALE), HCA Holdings Inc (NYSE:HCA) - share market updates (press release)
06/09/16 05:44 AMEarnings Stocks Analysis: Galena Biopharma, Inc. (NASDAQ:GALE), Navistar International Corporation (NYSE:NAV) - Beacon Chronicle
06/08/16 04:22 PMBiotech Beat: Analysts Chime In on Sarepta Therapeutics Inc (SRPT), Galena Biopharma Inc (GALE) and CytRx ... - Smarter Analyst
06/08/16 04:22 PMHC Stocks Watchful: Galena Biopharma Inc (NASDAQ:GALE), CVS Health Corp (NYSE:CVS) - share market updates (press release)
06/08/16 04:22 PMInsider Trading News: Tesla Motors Inc (TSLA), Fitbit Inc (FIT), Galena Biopharma Inc (GALE) and Qorvo Inc (QRVO) - Smarter Analyst
06/08/16 05:46 AMAnalyst Opinions on: Galena Biopharma, Inc. (NASDAQ:GALE), Las Vegas Sands Corp. (NYSE:LVS) - Beacon Chronicle
06/07/16 09:50 PMForm 4 Galena Biopharma, Inc. For: Jun 01 Filed by: Dunlap Ryan - StreetInsider.com
06/07/16 04:15 PMEye Catching Stock: Galena Biopharma, Inc. (NASDAQ:GALE) - News Oracle
06/07/16 04:15 PMPrice Target Summary Report: Companhia Siderurgica Nacional (NYSE:SID), Galena Biopharma, Inc. (NASDAQ:GALE) - Beacon Chronicle
06/07/16 04:15 PMRoth Capital Maintains Buy on Galena Biopharma Inc (GALE) and Mast Therapeutics Inc (MSTX) Following Clinical ... - Smarter Analyst
06/07/16 04:15 PMBiotech Beat: Analysts Chime In On Sarepta Therapeutics Inc (SRPT), Galena Biopharma Inc (GALE), CytRx ... - Smarter Analyst
06/07/16 06:23 AMSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galena Biopharma, Inc. for Potential Breaches ... - PR Newswire (press release)
06/07/16 06:12 AMSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galena Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors - [PR Newswire] - NEW YORK, June 7, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
06/06/16 09:35 PMBRIEF-Galena Biopharma's GALE-301 well-tolerated based on primary analysis - Reuters
06/06/16 09:35 PMCompany Update (NASDAQ:GALE): Galena Biopharma Inc Presents GALE-301 Phase 1/2a Primary Analysis at the ... - Smarter Analyst
06/06/16 04:01 PMStock under consideration: Galena Biopharma, Inc. (NASDAQ:GALE) - News Oracle
06/06/16 02:12 PMGalena Offers GALE-301 Phase 1/2a Primary Analysis at ASCO - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the primary analysis from the Company's GALE-301 Phase 1/2a clinical trial at the American Society of Clinical Oncology Annual Meeting 2016. GALE-301 is a cancer immunotherapy consisting of a peptide derived from Folate Binding Protein (FBP) combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the prevention of cancer recurrence in ovarian and endometrial cancer patients in the adjuvant setting. The poster, entitled, "The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, E39 + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence," demonstrated that the vaccine is well tolerated and immunogenic. In the optimal dose group, the results demonstrate potential clinical benefit for GALE-301 to prevent recurrence in these patients, and that boosters may sustain this effect. The Phase 1/2a trial began as a dose-escalation Phase 1 trial, transitioning to a Phase 2a comparing expanded dose cohorts with a total of 51 patients enrolled, n=29 in the vaccine group (VG) and n=22 in the control group (CG). After a median follow-up of 16 months, the overall recurrence rate was 44.8% in the VG versus 54.5% in the CG (p=0.58), with a recurrence rate of only 23.5% in those patients who received ...Full story available on Benzinga.com
06/06/16 01:01 PM2:01 pm Galena Biopharma announces the primary analysis from Gale-301 Phase 1/2a clinical trial at the ASCO annual meeting -
06/06/16 01:00 PMGalena Biopharma Presents GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016 - [GlobeNewswire] - SAN RAMON, Calif., June 06, 2016-- Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical ...
06/06/16 07:34 AMHC Stocks Highlights: MannKind Corporation (NASDAQ:MNKD), Galena Biopharma Inc (NASDAQ:GALE) - share market updates (press release)
06/06/16 07:34 AMGalena Biopharma Inc (GALE) Receives Buy Rating from FBR & Co. - Let Me Know About This
06/04/16 04:08 PMThese 2 Catalysts Helped Push Galena Biopharma, Inc. 31% Higher in May - Motley Fool
06/04/16 05:41 AMThese 2 Catalysts Helped Push Galena Biopharma, Inc. 31% Higher in May -
06/03/16 10:23 PMBiotech Beat: FBR Analysts Weigh In on Galena Biopharma Inc (GALE), Peregrine Pharmaceuticals (PPHM) and ... - Smarter Analyst
06/03/16 04:26 PMStocks Update: Galena Biopharma, Inc. (NASDAQ:GALE) , Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Is stories
06/03/16 04:26 PMEarnings Report: Huntington Bancshares Incorporated (NASDAQ:HBAN), Galena Biopharma, Inc. (NASDAQ:GALE) - Beacon Chronicle
06/03/16 05:32 AMGalena Biopharma, Inc. (NASDAQ:GALE) Stock Update & Estimates - Stock Tick Tock - Galena Biopharma, Inc. (NASDAQ:GALE) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Galena Biopharma, Inc. (NASDAQ:GALE) to post earnings of $-0.07 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued ...and more »
06/02/16 04:22 PMHC Stocks Reports: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Galena Biopharma Inc (NASDAQ:GALE) - share market updates (press release) - HC Stocks Reports: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Galena Biopharma Inc (NASDAQ:GALE)share market updates (press release)Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Wednesday session in green amid volatile trading. The shares closed up +1.30 points or 4.57% at $29.75 with 32,987,750 shares getting traded. Post opening the session at $28.36, the shares hit ...and more »
06/02/16 04:22 PMStocks Earnings Analysis Report: Galena Biopharma, Inc. (NASDAQ:GALE), General Motors Company (NYSE:GM) - Beacon Chronicle - Beacon ChronicleStocks Earnings Analysis Report: Galena Biopharma, Inc. (NASDAQ:GALE), General Motors Company (NYSE:GM)Beacon ChronicleGalena Biopharma, Inc. (NASDAQ:GALE) currently has High Price Target of $5. The Low and Mean Price Targets are $2 and $4 respectively. These price targets are a consensus analysis of 4 brokers. When having a look at Recommendation Trends of the ...and more »
06/02/16 04:22 PMMid-day Stocks to Track: Dermira Inc (NASDAQ:DERM), Galena Biopharma Inc (NASDAQ:GALE), Catalent Inc (NYSE ... - The Point Review - The Point ReviewMid-day Stocks to Track: Dermira Inc (NASDAQ:DERM), Galena Biopharma Inc (NASDAQ:GALE), Catalent Inc (NYSE ...The Point ReviewShares of Dermira Inc (NASDAQ:DERM) fell -5.23% to $30.44 at 12:03 PM EDT. The stock attained the volume of 1.29 Million shares recently versus average trading volume of 258,744 shares. If we take a look on its volatility, 3.60 percent was seen in a ...and more »
06/02/16 12:49 PM10 Potentially Game-Changing Cancer Immunotherapies You Should Be Following -
06/02/16 05:00 AMWhy Galena Biopharma, Inc. Was on the Fast Track to a Higher Stock Price Today - Motley Fool - Motley FoolWhy Galena Biopharma, Inc. Was on the Fast Track to a Higher Stock Price TodayMotley FoolWhat: Galena Biopharma (NASDAQ:GALE) was up 18% at 1:20 p.m. EDT after announcing this morning that the Food and Drug Administration gave a Fast Track designation to the biotech's NeuVax breast cancer drug. So what: Galena is testing NeuVax in ...Option Bulls Flock to Galena Biopharma Inc (GALE) After FDA NodSchaeffers Research (blog)Why Galena Biopharma Inc (GALE), Michael Kors Holdings Ltd (KORS) and Valeant Pharmaceuticals Intl Inc (VRX) Are ...Investorplace.comDemandware Inc (DWRE), Galena Biopharma Inc (GALE), Can Fite Biopharma Ltd (ADR) (CANF), Michael Kors ...TCCThe Point Review -Smarter Analyst -CWRU Observerall 23 news articles »
About Galena Biopharma

Galena Biopharma logoGalena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GALE
  • CUSIP:
Key Metrics:
  • Previous Close: $2.15
  • 50 Day Moving Average: $1.79
  • 200 Day Moving Average: $1.29
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $380.04M
  • Current Quarter EPS Consensus Estimate: $-0.29 EPS
Additional Links:
Galena Biopharma (NASDAQ:GALE) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha